Moderna Inc.

Alpha Score of 41 reflects weak overall profile with weak momentum, weak value, poor quality, moderate sentiment.

Moderna, Inc. is a biotechnology company specializing in the research, development, and provision of messenger RNA (mRNA) medicines in the United States, Europe, and internationally. Its primary function centers on creating innovative therapeutics and vaccines using mRNA technology, targeting a broad spectrum of diseases including infectious, oncological, rare, and cardiovascular conditions. Key products include Spikevax, an mRNA-based COVID-19 vaccine, alongside mRESVIA for respiratory syncytial virus (RSV), and investigational vaccines for seasonal influenza, cytomegalovirus, Epstein-Barr virus, norovirus, Zika, and bacterial diseases like Lyme. In oncology, it advances individualized neoantigen therapies and immune modulation treatments; for rare diseases, it develops therapies for propionic acidemia, glycogen storage disease, and cystic fibrosis. With a pipeline of over 40 clinical-stage products, Moderna, Inc. plays a pivotal role in the biopharmaceutical sector, driving advancements in precision medicine and public health responses to pandemics and endemic threats through its mRNA platform.